Global GMP Grade Salt-Active Nuclease (SAN) Market Strategic Research Report

Scope of the Report

The global GMP Grade Salt-Active Nuclease (SAN) market size is predicted to grow from US$ 18.33 million in 2025 to US$ 97 million in 2032; it is expected to grow at a CAGR of 24.0% from 2026 to 2032.

In 2025, globalGMP Grade Salt-Active Nuclease (SAN) production reached approximately 18.78 K MU, with an average global market price of around 998 USD per MU.

GMP Grade Salt-Active Nuclease (SAN) refers to a GMP-grade, non-specific endonuclease enzyme designed or engineered to degrade residual host-cell nucleic acids, including single-stranded and double-stranded DNA and RNA, under medium- to high-salt bioprocessing conditions. It is mainly used in the manufacturing and purification of viral vectors, vaccines, recombinant proteins and other biologics, where conventional nucleases may lose efficiency under elevated salt concentrations. GMP-grade SAN products are manufactured and quality-controlled under GMP-oriented systems, making them suitable for process development and commercial biomanufacturing workflows where residual DNA/RNA clearance, impurity reduction and regulatory documentation are required.

The core value of GMP Grade Salt-Active Nuclease (SAN) lies in its ability to maintain strong nucleic acid degradation performance under medium- to high-salt bioprocessing conditions, addressing the limitation of conventional nucleases whose activity may decline in high-salt environments. In the manufacturing of AAV, lentiviral vectors, adenoviral vectors, vaccines and recombinant proteins, residual host-cell DNA/RNA, high lysate viscosity and heavy downstream purification burden remain major process challenges. By directly degrading residual nucleic acids in salt-containing process streams, SAN can reduce the need for additional desalting, buffer exchange or process redesign, helping manufacturers improve purification efficiency, simplify workflows and strengthen consistency in GMP production.

As cell and gene therapy, viral vector manufacturing, vaccines and next-generation biologics move further toward scale-up, regulatory compliance and commercial production, demand is increasing for GMP-grade process enzymes with robust quality systems, batch-to-batch consistency, regulatory documentation and broad process compatibility. Compared with research-grade nucleases, GMP Grade SAN is not merely an enzyme reagent, but a critical biomanufacturing tool that supports process efficiency, impurity control and regulatory readiness. Looking ahead, as high-salt purification strategies become more widely adopted in AAV and related biologics workflows, and as CDMOs and biopharma companies place greater emphasis on residual nucleic acid control, GMP Grade Salt-Active Nuclease is well positioned to become an important enabling material in advanced biomanufacturing.

The upstream raw materials for GMP Grade Salt-Active Nuclease (SAN) mainly include recombinant expression systems, microbial fermentation media, GMP-grade buffer salts and stabilizers, chromatography packing materials, filtration/ultrafiltration consumables, quality control reagents, and pharmaceutical packaging materials. Representative suppliers include Thermo Fisher Scientific, Merck KGaA/MilliporeSigma, Avantor, Cytiva, Sartorius, Repligen, Kerry, BD Difco, Organotechnie/Solabia, SCHOTT Pharma, Stevanato Group, and West Pharmaceutical. Downstream applications are primarily in recombinant proteins, viral vaccines, and viral vectors. Typical customers include Thermo Fisher, Lonza, Oxford Biomedica, Sanofi, GSK, Merck, Pfizer, AstraZeneca, SK Bioscience, Sinopharm Group, and Sinovac Biotech, among others.

GMP Grade Salt-Active Nuclease (SAN) varies greatly depending on product type, process path, and degree of automation, with industry gross margins typically ranging from 70% to 80%.

Global key GMP Grade Salt-Active Nuclease (SAN) players cover ArcticZymes Technologies, New England Biolabs, QIAGEN N.V., Merck KGaA, c-LEcta GmbH, etc.

This report presents a comprehensive overview of the global GMP Grade Salt-Active Nuclease (SAN) market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 200 mM NaCl Below
• 200-400 mM NaCl
• 400 mM NaCl Above

Segment by Target Impurity

• Host DNA Clearance Nuclease
• Host RNA Clearance Nuclease
• Others

Segment by Form

• Liquid
• Lyophilized Powder

Segment by Application

• Recombinant Protein
• Viral Vaccine
• Viral Vector
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global GMP Grade Salt-Active Nuclease (SAN) market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Recombinant Protein, Viral Vaccine, Viral Vector evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact